Emergent BioSolutions - EBS Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares.
View EBS analyst ratings or view top-rated stocks.

6 equities research analysts have issued 1-year price objectives for Emergent BioSolutions' stock. Their EBS share price forecasts range from $25.00 to $55.00. On average, they anticipate the company's stock price to reach $36.75 in the next year. This suggests a possible upside of 172.8% from the stock's current price.
View analysts price targets for EBS or view top-rated stocks among Wall Street analysts.

Emergent BioSolutions' stock was trading at $11.81 at the beginning of the year. Since then, EBS shares have increased by 14.1% and is now trading at $13.47.
View the best growth stocks for 2023 here.

Emergent BioSolutions saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 5,570,000 shares, an increase of 63.3% from the December 31st total of 3,410,000 shares. Based on an average daily trading volume, of 959,600 shares, the days-to-cover ratio is presently 5.8 days. Currently, 13.7% of the company's stock are short sold.
View Emergent BioSolutions' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our EBS earnings forecast.

Emergent BioSolutions Inc. (NYSE:EBS) posted its earnings results on Tuesday, November, 8th. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.06) by $1.21. The biopharmaceutical company had revenue of $240 million for the quarter, compared to analyst estimates of $268.17 million. Emergent BioSolutions had a trailing twelve-month return on equity of 9.52% and a net margin of 3.54%.

Emergent BioSolutions updated its FY 2022 earnings guidance on Friday, January, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.10 billion-$1.12 billion, compared to the consensus revenue estimate of $1.09 billion.

38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Emergent BioSolutions' stock is owned by a number of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.12%), Strs Ohio (0.10%), Values First Advisors Inc. (0.07%), Yousif Capital Management LLC (0.05%), SummerHaven Investment Management LLC (0.05%) and Comerica Bank (0.05%). Insiders that own company stock include Adam Havey, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Richard S Lindahl, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi.
View institutional ownership trends.

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EBS stock can currently be purchased for approximately $13.47.

Emergent BioSolutions (NYSE:EBS) has a market capitalization of $672.02 million and generates $1.79 billion in revenue each year. The biopharmaceutical company earns $230.90 million in net income (profit) each year or $0.78 on an earnings per share basis.

The company employs 2,416 workers across the globe.

Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The official website for the company is www.emergentbiosolutions.com. The biopharmaceutical company can be reached via phone at (240) 631-3200, via email at burrowsr@ebsi.com, or via fax at 301-795-1899.